Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload

  • Ware R
  • Schultz W
  • Yovetich N
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

BACKGROUND: Stroke occurs in 5-10% of children with sickle cell anemia (SCA) and has a high (>50%) risk of recurrence without therapy. Chronic monthly erythrocyte transfusions effectively prevent recurrent stroke, but their long-term use is limited by serious side effects, including iron overload. An alternative to transfusion for secondary stroke prevention in SCA is needed, especially one that also improves the management of iron overload. METHODS: Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) is an NHLBI-sponsored Phase III multicenter randomized controlled clinical trial for children with SCA, stroke, and iron overload (NCT00122980). The primary goal of SWiTCH is to compare 30 months of alternative therapy (hydroxyurea and phlebotomy) with standard therapy (transfusions and chelation) for the prevention of secondary stroke and reduction of transfusional iron overload. DISCUSSION: SWiTCH has several distinctive study features including novel methodological and design components: (1) composite primary endpoint including both stroke recurrence rate and iron burden; (2) non-inferiority design with an "acceptable" increased stroke risk; (3) transfusion goals based on current academic community practices; (4) special oversight for the enrollment and randomization process; (5) overlap treatment period within the alternative treatment arm; (6) masking of the overall trial Principal Investigator to treatment results; (7) inclusive independent stroke adjudication process for all suspected new neurological events; and (8) periodic therapeutic phlebotomy program to alleviate iron overload. CONCLUSION: Investigation of alternative treatments in SWiTCH could lead to changes in the management of cerebrovascular disease for selected patients with SCA, stroke, and iron overload.

Author-supplied keywords

  • 1200
  • 2
  • 30
  • 4
  • Adolescent
  • Adult[checkword]
  • Anemia
  • Anemia,Sickle Cell [complications] [therapy]
  • Arm
  • Article
  • Blood
  • Cancer
  • Chelation
  • Chelation Therapy
  • Child,Preschool[checkword]
  • Child[checkword]
  • Children
  • Clinical Trial
  • Clinical-Trial
  • Community
  • Controlled Clinical Trial
  • Controlled Trial
  • Controlled-Trial
  • Disease
  • Effects
  • Erythrocyte
  • Erythrocyte Transfusion
  • Erythrocyte Transfusion [adverse effects]
  • Goals
  • Humans[checkword]
  • Hydroxyurea
  • Hydroxyurea [therapeutic use]
  • Iron
  • Iron Overload
  • Iron Overload [etiology] [prevention & control] [
  • Lead
  • Management
  • Multicenter
  • Multicenter Study
  • Patient
  • Patients
  • Phlebotomy
  • Prevention
  • Randomization
  • Randomized Controlled Trial
  • Randomized-Clinical-Trial
  • Recurrence
  • Research
  • Risk
  • Sickle Cell
  • Sickle Cell Anemia
  • Side Effect
  • Stroke
  • Stroke [etiology] [prevention & control] [therapy
  • TRIAL
  • Therapy
  • Young Adult[checkword]
  • methods
  • transfusion
  • treatment

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • R E Ware

  • W H Schultz

  • N Yovetich

  • N A Mortier

  • O Alvarez

  • L Hilliard

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free